GSK plc (NYSE:GSK) Position Reduced by Yousif Capital Management LLC

Yousif Capital Management LLC reduced its stake in GSK plc (NYSE:GSK) by 24.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 23,806 shares of the pharmaceutical company’s stock after selling 7,509 shares during the period. Yousif Capital Management LLC’s holdings in GSK were worth $805,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Eastern Bank bought a new stake in shares of GSK in the 3rd quarter worth $26,000. Crews Bank & Trust bought a new stake in GSK in the fourth quarter worth $26,000. ST Germain D J Co. Inc. boosted its position in GSK by 195.5% during the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 522 shares during the period. Sunbelt Securities Inc. grew its position in shares of GSK by 73.8% in the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock valued at $29,000 after purchasing an additional 302 shares during the last quarter. Finally, Concord Wealth Partners increased its position in GSK by 231.8% during the third quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock worth $32,000 after acquiring an additional 547 shares during the period. Institutional investors own 15.74% of the company’s stock.

GSK Price Performance

Shares of NYSE:GSK opened at $36.20 on Friday. GSK plc has a 12 month low of $31.72 and a 12 month high of $45.92. The firm has a 50 day moving average of $34.42 and a 200-day moving average of $37.46. The company has a current ratio of 0.78, a quick ratio of 0.53 and a debt-to-equity ratio of 1.12. The stock has a market capitalization of $75.02 billion, a PE ratio of 22.76, a PEG ratio of 1.42 and a beta of 0.64.

GSK (NYSE:GSK) last announced its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. On average, equities research analysts predict that GSK plc will post 4.07 EPS for the current fiscal year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be paid a $0.3932 dividend. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.34%. This is an increase from GSK’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, February 21st. GSK’s payout ratio is currently 93.08%.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Deutsche Bank Aktiengesellschaft lowered shares of GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Jefferies Financial Group cut GSK from a “buy” rating to a “hold” rating and reduced their target price for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 7th. Morgan Stanley started coverage on shares of GSK in a research note on Wednesday. They issued an “equal weight” rating on the stock. Finally, Guggenheim downgraded GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Seven investment analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, GSK presently has an average rating of “Moderate Buy” and an average target price of $43.25.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.